- Home
- GALT vs ELDN Comparison
GALT vs ELDN Comparison
Compare GALT & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GALT
- ELDN
- Stock Information
- Founded
- GALT 2000
- ELDN 2004
- Country
- GALT United States
- ELDN United States
- Employees
- GALT N/A
- ELDN N/A
- Industry
- GALT Biotechnology: Pharmaceutical Preparations
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- GALT Health Care
- ELDN Health Care
- Exchange
- GALT Nasdaq
- ELDN Nasdaq
- Market Cap
- GALT 232.3M
- ELDN 202.4M
- IPO Year
- GALT N/A
- ELDN N/A
- Fundamental
- Price
- GALT $4.60
- ELDN $2.71
- Analyst Decision
- GALT Strong Buy
- ELDN Strong Buy
- Analyst Count
- GALT 3
- ELDN 2
- Target Price
- GALT $6.00
- ELDN $12.50
- AVG Volume (30 Days)
- GALT 241.8K
- ELDN 683.9K
- Earning Date
- GALT 08-14-2025
- ELDN 08-14-2025
- Dividend Yield
- GALT N/A
- ELDN N/A
- EPS Growth
- GALT N/A
- ELDN N/A
- EPS
- GALT N/A
- ELDN 0.21
- Revenue
- GALT N/A
- ELDN N/A
- Revenue This Year
- GALT N/A
- ELDN N/A
- Revenue Next Year
- GALT N/A
- ELDN N/A
- P/E Ratio
- GALT N/A
- ELDN $12.78
- Revenue Growth
- GALT N/A
- ELDN N/A
- 52 Week Low
- GALT $0.73
- ELDN $2.38
- 52 Week High
- GALT $4.71
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- GALT 69.41
- ELDN 46.99
- Support Level
- GALT $3.93
- ELDN $2.54
- Resistance Level
- GALT $4.35
- ELDN $2.66
- Average True Range (ATR)
- GALT 0.27
- ELDN 0.12
- MACD
- GALT 0.03
- ELDN 0.03
- Stochastic Oscillator
- GALT 91.67
- ELDN 60.61
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.